Cardiol Therapeutics Valuation
| CRDL Stock | CAD 1.52 0.08 5.00% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Cardiol Therapeutics shows a prevailing Real Value of C$1.4 per share. The current price of the firm is C$1.52. Our model approximates the value of Cardiol Therapeutics from analyzing the firm fundamentals such as Current Valuation of 117.29 M, shares owned by insiders of 4.00 %, and Return On Equity of -1.6 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cardiol Therapeutics' valuation include:
Price Book 12.7513 | Enterprise Value | Enterprise Value Ebitda 0.4057 | Price Sales 1.3 K | Enterprise Value Revenue 230.5152 |
Overvalued
Today
Please note that Cardiol Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Cardiol Therapeutics is based on 3 months time horizon. Increasing Cardiol Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cardiol Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cardiol Stock. However, Cardiol Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.52 | Real 1.4 | Hype 1.52 |
The intrinsic value of Cardiol Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cardiol Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cardiol Therapeutics Class helps investors to forecast how Cardiol stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cardiol Therapeutics more accurately as focusing exclusively on Cardiol Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cardiol Therapeutics' intrinsic value based on its ongoing forecasts of Cardiol Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cardiol Therapeutics' closest peers.
Cardiol Therapeutics Cash |
|
Cardiol Valuation Trend
Knowing Cardiol Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Cardiol Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Cardiol Therapeutics Total Value Analysis
Cardiol Therapeutics Class is currently estimated to have takeover price of 117.29 M with market capitalization of 130.57 M, debt of 174.34 K, and cash on hands of 59.47 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cardiol Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
117.29 M | 130.57 M | 174.34 K | 59.47 M |
Cardiol Therapeutics Asset Utilization
One of the ways to look at asset utilization of Cardiol is to check how much profit was generated for every dollar of assets it reports. Cardiol Therapeutics Class shows a negative utilization of assets of -0.79 percent, losing C$0.007907 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cardiol Therapeutics Class shows how discouraging it operates for each dollar spent on its assets.Cardiol Therapeutics Ownership Allocation
Cardiol Therapeutics holds a total of 81.6 Million outstanding shares. Cardiol Therapeutics Class shows 4.0 percent of its outstanding shares held by insiders and 12.18 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cardiol Therapeutics Profitability Analysis
Net Loss for the year was (28.13 M) with profit before overhead, payroll, taxes, and interest of 78.76 K.About Cardiol Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cardiol Therapeutics Class. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cardiol Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Cardiol Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cardiol Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cardiol Therapeutics. We calculate exposure to Cardiol Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cardiol Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -223.5 K | -212.3 K | |
| Pretax Profit Margin | (361.53) | (379.61) | |
| Operating Profit Margin | (519.63) | (545.61) | |
| Net Loss | (282.52) | (296.65) |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.